Nucletron, an Elekta company, receives FDA 510(k) clearance for precise Vaginal CT/MR Multi Channel Applicator

Nucletron, an Elekta company, receives FDA 510(k) clearance for precise
Vaginal CT/MR Multi Channel Applicator

During the first day of the annual conference for the American Society
for Radiation Oncology (ASTRO) in Miami, Nucletron, an Elekta company,
today announced that it has received FDA 510(k) clearance for its new
Vaginal CT/MR Multi Channel (VCMC) Applicator, offering a brachytherapy
solution that enables very precise dose delivery for gynecologic
cancers. Combined with Oncentra® treatment planning software this
applicator makes it possible to reach new levels of workflow
optimization.

“Our new vaginal applicator has been developed to fulfill the wish of
many radiotherapists to deliver the radiation dose where it matters
most, with greater precision. Thanks to a unique design featuring
channels which follow the curve of the applicator tip, health care
providers can now deliver radiation directly to the target area, while
sparing surrounding healthy tissues,” says Jos Lamers, Executive Vice
President, Elekta Brachytherapy Solutions. “The recent results of the
PORTEC-2 study underlined the role of brachytherapy in preventing cancer
recurrence in women following surgery for uterine cancer, while
resulting in significantly lower side effects, and significantly better
quality of life. The new VCMC will allow health care teams to build on
these results in treating women with gynecologic cancers.”

Bringing the right dose to the right place is critical in successful
vaginal brachytherapy. The Vaginal CT/MR Multi Channel Applicator
provides accurate target coverage and maximizes conformity in the
treatment of gynecologic cancers. It features Nucletron's Precise Dose
Delivery Solution (PDDSTM) technology, an innovative system that loads
several source channels in the applicator, with a unique catheter
geometry. This results in a dwell position that is very close to the
target area, allowing for greater treatment precision. This applicator
is designed to optimize the dose distribution to help prevent
recurrence, while minimizing toxicity, side effects and impaired quality
of life.

The VCMC Applicator is easy to assemble, clean and sterilize and
integrates seamlessly with Nucletron's Oncentra treatment planning
software. Automatic reconstruction of the exact geometry of the
applicator dramatically improves the speed of planning, and ensures
precise and reproducible placement of the applicator.

The Vaginal CT/MR Multi Channel Applicator will be on display for
demonstration during ASTRO's annual conference October 2-4 in the
Nucletron Booth #2001.

For further information, please contact:

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
stina.thorman@elekta.com (stina.thorman@elekta.com)

Gert van Santen, Communications Director, Nucletron an Elekta company
Tel +31653561242, e-mail:
gert.vansanten@nl.nucletron.com (gert.vansanten@nl.nucletron.com)

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 12.00 CET on
October 2, 2011. 

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy, radiosurgery and brachytherapy, as well
as workflow enhancing software systems across the spectrum of cancer
care.

Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,300 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker EKTAb.
Website: www.elekta.com (http://www.elekta.com/). 
About Nucletron, an Elekta company
Nucletron was recently acquired by Elekta and provides state of the art
radiotherapy solutions for cancer treatment that meet the evolving needs
of patients, their caregivers and healthcare professionals around the
world. Nucletron has unmatched global leadership in brachytherapy, a
very precise, highly effective and well-tolerated treatment option for
healthcare providers, tailored to the needs of individual patients.  The
company works with clinical teams to constantly improve and develop an
innovative portfolio of integrated products, software and services that
assures excellent patient outcomes. Nucletron products are available in
more than 100 countries around the world. Website:
https://www.nucletron.com/ (http://www.nucletron.com/)